Picture of Sinomab Bioscience logo

3681 Sinomab Bioscience Income Statement

0.000.00%
hk flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Annual income statement for Sinomab Bioscience, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue00025.90
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses80.6274119304274
Operating Profit-80.6-274-119-278-274
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes-83.6-276-123-288-284
Provision for Income Taxes
Net Income After Taxes-83.6-276-123-288-284
Minority Interest
Net Income Before Extraordinary Items
Net Income-83.6-276-123-288-284
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-83.6-276-123-288-284
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.101-0.33-0.122-0.29-0.304
Dividends per Share